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Central GIP signaling stimulates peripheral GIP release and promotes
insulin and pancreatic polypeptide secretion in nonhuman primates.
Am J Physiol Endocrinol Metab 311: E661–E670, 2016. First pub-
lished August 16, 2016; doi:10.1152/ajpendo.00166.2016.—Glucose-
dependent insulinotropic polypeptide (GIP) has important actions on
whole body metabolic function. GIP and its receptor are also present
in the central nervous system and have been linked to neurotrophic
actions. Metabolic effects of central nervous system GIP signaling
have not been reported. We investigated whether centrally adminis-
tered GIP could increase peripheral plasma GIP concentrations and
influence the metabolic response to a mixed macronutrient meal in
nonhuman primates. An infusion and sampling system was developed
to enable continuous intracerebroventricular (ICV) infusions with
serial venous sampling in conscious nonhuman primates. Male ba-
boons (Papio sp.) that were healthy and had normal body weights
(28.9  2.1 kg) were studied (n  3). Animals were randomized to
receive continuous ICV infusions of GIP (20 pmol·kg1·h1) or
vehicle before and over the course of a 300-min mixed meal test (15
kcal/kg, 1.5g glucose/kg) on two occasions. A significant increase in
plasma GIP concentration was observed under ICV GIP infusion
(66.5 8.0 vs. 680.6 412.8 pg/ml, P 0.04) before administration
of the mixed meal. Increases in postprandial, but not fasted, insulin
(P  0.01) and pancreatic polypeptide (P  0.04) were also observed
under ICV GIP. Effects of ICV GIP on fasted or postprandial glucagon,
glucose, triglyceride, and free fatty acids were not observed. Our data
demonstrate that central GIP signaling can promote increased plasma GIP
concentrations independent of nutrient stimulation and increase insulin
and pancreatic polypeptide responses to a mixed meal.
glucose-dependent insulinotropic polypeptide; brain; intracerebroven-
tricular; nonhuman primate
GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE (GIP) is a 42-
amino acid peptide released primarily from enteroendocrine K
cells in response to nutrient stimulation. Although originally
described for its role in gastric acid secretion (5), GIP is an
important incretin peptide and an essential driver of normal
postprandial insulin secretion (17). Beyond its insulinotropic
and intestinal actions, GIP also has effects on adipose tissue,
bone, the heart and vasculature, pancreatic -cells, and, im-
portantly, the central nervous system (8).
The GIP receptor (GIPR) is expressed in multiple regions of
the mammalian brain (32, 45), and immunohistochemically
detected GIP has also been shown in the rat brain (36). Brain
GIP action is now linked to neurotrophic effects and aug-
mented synaptic plasticity in rodents (20–22, 29, 31, 39, 44,
53). Whether central GIP signaling can generate effects outside
of the central nervous system is unclear (2, 16, 38). In support
of such an action for GIP, other metabolically active intestinal
peptides (6, 41) are known to generate peripheral effects
through actions in the brain and, thereby, modulate metabolic
function through the gut-brain axis.
A series of recent studies in a canine model has provided
evidence for a brain-gut signaling pathway capable of modu-
lating GIP concentrations in the peripheral circulation. These
studies showed that plasma GIP concentrations were increased
by intracerebroventricular (ICV) administration of neuropep-
tide Y (48), bombesin (51), and neurotensin (50) and decreased
by ICV insulin (49). Earlier studies also demonstrated nutrient-
independent effects of bombesin-like peptides on GIP release
in enteroendocrine cell lines, suggesting an independent neural
influence on GIP secretion from K cells (35). Combined, these
studies support a role for neuroregulation in peripheral GIP
release and indicate the presence of an efferent signal from the
brain to the gut that can modulate GIP release independent of
nutrient stimulation.
We investigated whether centrally administered GIP could
increase peripheral plasma GIP concentrations and influence
the metabolic response to a mixed macronutrient meal in
conscious healthy nonhuman primates. Here, we present evi-
dence that central nervous system GIP signaling generates an
efferent signal that stimulates GIP release into the peripheral
circulation and influences postprandial islet peptide secretion.
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METHODS
Test subjects. Four healthy young adult male baboons (Papio sp.)
were originally selected for study; n  3 animals completed the study
protocol. Before the initiation of study activities, all animals were
housed in social groups in outdoor enclosures at the Southwest
National Primate Research Center according to the National Institutes
of Health Guide for the Care and Use of Laboratory Animals. All
animals were then transferred to a vivarium and housed in species-
appropriate metabolic cages and were maintained at constant room
temperature and humidity in a 12:12-h light-dark cycle for the dura-
tion of the study activities. The indoor housing environment was
enriched using food items, food puzzles, chewable toys, audio, and
visual tools according to Association for Assessment and Accredita-
tion of Laboratory Animal Care guidelines. A licensed veterinarian
performed a standard health assessment including a physical exami-
nation and serum chemistry and hematology profiling in all animals
before their inclusion in the study. All animals were healthy with no
history of medical illness. Animals were fed a standard nonhuman
primate diet [5LE0 solid feed, LabDiet, PMI, St. Louis, MO; this diet
contains 3.26 kcal/g with 13.8% fat, 67.2% carbohydrate (3% sugar),
and 19% protein as a percentage of total energy] between 0800 and
1800 daily and had continuous access to water. All study procedures
were approved by the Institutional Animal Care and Use Committee
of the Texas Biomedical Research Institute (San Antonio, TX).
Tether system adaptation period. After an initial period of accli-
mation to the indoor housing environment, n  12 animals (initial
selection pool) were evaluated for adaptation to single caging and to
the presence of a tether jacket and tether coil for a period of 3 wk. This
“sham tethering” approach has been described in detail elsewhere
(14). In brief, each animal was fitted to a customized cotton tether
jacket that was connected to a stainless steel coil that “tethered” the
animal to the cage ceiling. During this period, animals were assessed
daily for behavior and food intake and were sedated weekly for
physical and biochemical health assessments and to enable adjust-
ments to the tethering system to ensure optimal comfort and function-
ality. Four animals were selected based on technician- and investiga-
tor-determined habituation to the housing environment and tether
system. These animals then underwent the following procedures in
preparation for study: 1) presurgical stereotaxic brain coordinate
identification, 2) implant of a lateral cerebral ventricular cannula, and
3) femoral vein catheterization surgery and connection of ventricular
and venous lines through the system. An overview of the study is
shown in Fig. 1, top. The experiments undertaken involved modifi-
cation of an extant vascular infusion and sampling system (3, 14) to
enable ICV infusion in alert singly caged nonhuman primates (27) and
are detailed below.
Presurgical stereotaxic brain coordinate identification. The se-
lected animals were prepared for ICV cannulation surgery. Each
baboon was sedated with ketamine (10 mg/kg im) and fitted to a
stereotaxic frame (model 1504, dog and monkey stereotaxic frame,
David Kopf Instruments, Tujunga, CA). The frame is designed to
enable the baboon to lie in a prone position with the head raised above
shoulder height. This initial fitting procedure was used to establish and
record accurate coordination points for cannula implant in the left
lateral cerebral ventricle of each animal. Specifically, the stereotaxic
frame was adjusted so that the lower edge of the frame’s eye rods was
parallel (in the same plane) to the center of the ear bars, thus
establishing a horizontal plane zero reference point for each animal
that was consistent with the Baboon Brain Atlas (15). Following from
this, the coordinates for the exact midpoint between the ends of the ear
bars were identified to establish the anterior-posterior zero-point
coordinate and the lateral left-to-right zero coordinate for the brain of
each animal. Animals were returned to their home cages immediately
after the coordinates were identified and recorded.
ICV cannula implant surgery. Seven days after stereotaxic coordi-
nate identification procedures, each animal was sedated with ketamine
(10 mg/kg im) and transported to a surgery room for ICV implant
surgery. Details of the ICV cannula implant surgery in baboons in our
laboratory have been previously published (3, 4, 43). Anesthesia was
induced and maintained with isoflurane inhalation [1.0–1.5% (vol/
vol)]. The stereotaxic frame was positioned according to the previ-
ously determined coordinates. Based on the identification of the
region of the lateral cerebral ventricle during frame fitting, a midline
incision along with blunt dissection was made to expose the cranium.
A hole (5-mm diameter) was drilled through the cranium at 19 mm
anterior to the ear bar and 1.0 mm left of the midline. The z-coordinate
location of the dura was then established by lowering the tip of the
cannula until it made contact with the dura. At this time, a pressure
transducer (SensorMedics, Yorba Linda, CA) was connected to record
hydrostatic pressure within the cannula. Sterile 0.9% NaCl solution
was infused through the cannula at a rate of 5 ml/h as the cannula was
slowly lowered in 1-mm increments through the cerebral tissue.
Hydrostatic pressure within the cannula was recorded in real time
using a strip chart recorder. The location of the lateral cerebral was
determined at the z-coordinate where hydrostatic pressure inside the
cannula decreased to zero. Lateral ventricular cannula placement was
then confirmed by fluoroscopic imaging of the lateral ventricular
space during delivery of a 1-ml bolus of iohexol (Omnipaque, GE
Healthcare, Princeton, NJ) through the cannula. All cannulas were
confirmed to be positioned in the lateral cerebral ventricle. The
location of the lateral cerebral ventricle was between 20 and 25 mm
inferior to the dura in all animals. The cannula was then fixed in place
by placing dental acrylic in and around the cranial hole. The external
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portion of the cannula was slowly pushed downward at a right angle
and positioned parallel to the surface of the skull. To anchor the dental
acrylic, self-tapping stainless steel screws were placed in the cranium
next to the cannula and additional dental acrylic was added to allow
sufficient coverage of the screws and the cannula. Twenty-gauge
polyvinyl tubing (Tygon S54HL microbore tubing, St. Gobain, Akron,
OH) was attached to the external end of the cannula and routed
subcutaneously to an exit site on the lower back of the animal. The
ventricular cannula line was slowly loaded with artificial cerebrospi-
nal fluid (aCSF) and connected to a miniosmotic pump containing
aCSF (Alzet, Palo Alto, CA), which was then implanted subcutane-
ously to maintain the patency of the ventricular infusion line and
cannula before connection to the infusion system, as previously
described (3). The cranial incision was closed with a 3-0 polyglactin
suture (Vicryl, Ethicon) so that the skin completely covered the
cannula and acrylic block. The incision site for the pump was closed
with a 3-0 suture (Vicryl, Ethicon). Animals were then returned to
their home cages for recovery.
ICV cannula surgery perioperative medications. Thirty minutes
before the surgical incision, each animal received a prophylactic dose
of Cefazolin (350 mg iv). Tramadol was administered intraoperatively
at a continuous infusion at a rate of 150 g/kg iv. Animals were
monitored continuously for 12 h in the immediate postoperative
period. Postoperatively, animals were dosed further with Tramadol
either with the injectable or oral form twice daily and received a single
dose of Zofan (2 mg). Cefazolin (25 mg/kg) was administered intra-
venously twice per day for 5 days after surgery.
Femoral vein catheterization surgery. Fourteen days after the ICV
cannula implant surgery was performed, a second surgery was per-
formed to implant a catheter (5-Fr Hydrocoat, Access Technologies,
Skokie, IL) in the femoral vein for sampling. Animals were sedated
with ketamine HCl (10 mg/kg im), and gas anesthesia was induced
and maintained using isoflurane [1.0–1.5% (vol/vol)]. A catheter was
then implanted in the femoral vein via a skin incision over the femoral
vessels in the femoral triangle of the inner thigh. This catheter was
then routed subcutaneously to the midscapular region of the back to
exit the skin at the location of the tether jacket backpack box and
locked using a syringe containing sterile 0.9% NaCl. The osmotic
pump was explanted and disconnected from the ICV line, and the ICV
line was also routed subcutaneously through an additional exit site
made 10 cm superior to that of the venous line and locked using
sterile 0.9% NaCl.
Venous catheter implants surgery perioperative medications. Dur-
ing surgery, animals were given a prophylactic analgesic (0.2 mg/kg
Metacam) and prophylactic antibiotic (25 mg/kg Cephazolin). After
surgery, Buprinex was administered (0.01 mg/kg qid) for 3 days and
antibiotic treatment [Cephazolin (25 mg/kg bid)] was continued for 7
days.
Connection of ICV infusion and venous sampling lines. After
surgery, animals were returned to their home cages. While the animals
remained under sedation, the venous catheter was connected through
the tethering system and kept patent using a continuous heparinized
saline (5 U/ml) infusion from a volumetric infusion pump maintained
at the top of the cage, as previously described (14). In parallel, the
ICV infusion line was also routed through the tether coil to the
infusion system at the top of the cage. The ICV line was kept patent
using a continuous infusion of aCSF (10 L/h) through a network
syringe pump (New Era Pump Systems, Farmingdale, NY), as de-
scribed below. The ICV line was connected through a pressure
transducer positioned inside the tether jacket backpack box at this
time, as has been previously described for arterial lines (3). The line
dead space was also measured at this time. A 4-wk recovery period
was provisioned after the femoral catheter implant surgery and before
the initiation of the experimental period. All animals underwent
detailed weekly physical, biochemical, and hematological health ex-
aminations under ketamine sedation throughout the postsurgery and
experimental periods. The physical examination was conducted by a
veterinarian and involved detailed inspection of the venous and
ventricular line exit site. Animal behavior was observed remotely
using a closed circuit network camera mounted on the wall opposite
the animal’s cage. No evidence for pain, distress, or malaise was
observed during the ICV infusion experiments.
ICV infusion system. We modified the aforementioned established
tethering system (14), which enables blood sampling and intravenous
infusion in singly caged conscious baboons, to include an ICV line
accessible from the cage exterior. As noted above, the cannula line
was routed through an exit site in the lower back region and was
connected through the stainless steel tether coil to the infusion
apparatus at the top of the cage. A continuous infusion of aCSF at 10
l/h was maintained through ICV infusion line using a Bluetooth-
modified network syringe pump (New Era Pump Systems) that was
attached to the tether mast at the top of the cage. ICV pumps were
controlled remotely using computer software (Syringe Pump Pro,
TBITC, Adelaide, SA, Australia) located in a room adjacent to the
animal housing rooms. To confirm patency of the ICV cannula
throughout the study, data from the ICV line pressure transducer were
acquired and continuously recorded using a Ponemah Physiology
Platform with P3 Plus Software for Windows (LDS Test Measure-
ment and Gould Instrument Systems, Valley View, OH). Any block-
age or disconnection in the ICV line was registered as an increase or
drop in line pressure, respectively. All ICV infusions were delivered
through a 0.20 m syringe filter unit attached to the syringe.
Animal habituation. Extensive habituation of the animals to tech-
nician presence was conducted at regular intervals during the 4-wk
recovery period. Animals were fully habituated to serial blood sam-
pling and to the mixed meal administration on 2 occasions/wk. All
experiments were performed by the same team of technicians and
investigators who worked with the baboons on a daily basis through-
out the entire prestudy and experimental period. One animal failed to
adapt to the tether system and was removed from study before
initiation of the experimental phase. The remaining animals (n  3)
adapted fully to the tether system, had normal food and water intakes,
and were weight stable before initiation of the mixed meal metabolic
experiments.
GIP peptide. Human GIP (1–42) peptide (Bachem, Torrence, CA)
was used for ICV infusion. Peptide was added to aCSF vehicle with
corrections for purity. We have found that the GIP (1–42) peptide
coding region of the baboon GIP gene has 100% identity with the
human ortholog. Baboon and human GIPR gene exon sequences also
have a high degree of identity. The baboon predicted GIP (1–42)
amino acid sequence together with GIP and GIPR interspecies com-
parisons are shown in detail in Table 1.
GIP peptide continuous ICV infusion experiments. Preliminary
studies were undertaken to determine an appropriate dose of ICV GIP.
A dose of 20 pmol·kg1·h1 was chosen for comparison with the
control condition. Animals were fasted overnight. ICV infusions were
undertaken on two occasions in each animal at 0 (aCSF control) and
20 pmol·kg1·h1 beginning at 2.0 h before the initiation of the mixed
meal tolerance tests. On each occasion, a baseline (fasted, pre-ICV
infusion) venous blood sample was taken at 135 min from the
initiation of the meal test (0 min) and a syringe containing the given
GIP dose was loaded on the syringe pump. At 120 min, the ICV
infusion was initiated remotely at a continuous infusion rate of 10 l/h
for each dose beginning with a 30-min priming infusion to clear the
ICV line dead space. Hence, ICV infusions were timed according to
measured dead space volume of each infusion line such that GIP
entered the ventricles 90 min before the start of the meal test. Each
infusion condition was conducted 1 wk apart, and the dose order was
randomized. All animals were tested in the fully conscious and alert
state.
Mixed meal test. Solid mixed meals were made using peanut butter,
graham crackers, and regular butter mixed to form small solid spheres
of 5 cm in diameter. Each mixed meal was presented to the baboon
in the form of three balls. Each complete meal contained 45% fat,
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45% carbohydrate, and 10% protein as total energy and were designed
to provide each baboon with 15 kcal and 1.5 g glucose per kilogram
of body weight. As described above, all animals were exposed to the
mixed meal before the initiation of the ICV experiments.
After an overnight fast of 14 h, baseline fasted venous blood
samples were taken at 30 and 15 min before the administration of
the mixed meal test. The meal was presented to the baboon in three
pieces over a 5-min period. Consumption of each piece of the meal
was observed and confirmed remotely using a networked video
camera animal monitoring system. Serial venous blood samples were
taken at 10, 20, 30, 45, 60, 90, 120, 180, and 300 min. after the meal
presentation. The ICV infusion was continued until completion of the
meal test at 300 min.
Peptide and metabolic substrate assays. Plasma concentrations of
glucose and triglyceride were determined using an ACE clinical
chemistry analyzer (Alfa Wasserman Diagnostic Technologies, West
Caldwell, NJ). Plasma nonesterified free fatty acids were measured
using colorimetric kits (NEFA-HR, Wako Diagnostics, Mountain
View, CA). Plasma insulin was determined using a DPC Immulite
1000 Analyzer (Diagnostics Products, Los Angeles, CA). Plasma
glucagon was measured using a commercial radioimmunoassay (GL-
32K, EMD Millipore Diagnostics, Billerica, MA). Plasma total GIP
and total pancreatic polypeptide (PP) were measured in plasma using
commercial ELISA kits (EZHGIP-54K and EZHPP-40K, EMD Mil-
lipore Diagnostics). All ELISA kits used were for the detection of
human forms of the peptides. Laboratory intra- and interassay coef-
ficients of variation were 15% for all immunoassays undertaken.
Gene sequencing. Total RNA was isolated from frozen tissue
(gastrointestinal and pancreas) using TRIzol Reagent (ThermoFisher
Scientific, Walthman, MA). RNA was treated with RQ1 DNAse
(Promega, Madison, WI) for 15 min at 37°C to remove traces of
genomic DNA. For the assessment of RNA purity and integrity, we
used standard methods of spectrophotometry and gel electrophoresis,
respectively. cDNA was synthesized using total RNA (0.5 g), a High
Capacity cDNA Reverse Transcription kit (ThermoFisher Scientific),
and oligo(dT) 12-18 primer (ThermoFisher Scientific) in 30 l of total
reaction volume. A primer set to amplify baboon GIP and GIPR
transcripts was designed using human and macaque sequences as
templates. For GIP, the sense primer was 5=-TCTGGAAGAGCTG-
GAAAGGA-3= and the antisense primer was 5=-CTATTCTG-
GAGTGGGGCTGA-3=; for GIPR, the sense primer was 5=-ATT-
GAGTGCCTACTGCGTGC-3= and the antisense primer was 5=-
TACACGAACCAGACCCTTCG-3=. PCR was carried out using 100
ng cDNA, 0.4 M of each primer, and the GoTaq PCR master mix kit
(Promega). The amplification reaction was carried out in a thermal
cycler (Veriti 96-well Thermal Cycler, ThermoFisher Scientific). The
amplification program used was as follows: an initial denaturation
step of 4 min at 94°C, 35 cycles of 30 s each at 94°C, 45 s at 60°C,
and 90 s at 72°C, and finally an elongation step of 6 min at 72°C. PCR
products were visualized on 1.0% agarose gels stained with ethidium
bromide and visualized under ultraviolet light. The amplified products
were cloned in the 3.5-kb XL-TOPO vector and transformed into the
electrocompetent Escherichia coli bacteria strain, One Shot TOP10,
according to the manufacturer’s specifications (Invitrogen, Carlsbad,
CA). Positive clones were sequenced using Big Dye Terminator Cycle
Sequencing Kit version 3.1 using specific oligos and/or M13 universal
primers. Reactions were analyzed in the ABI PRISM 3100 Genetic
Analyzer using Sequencing Analysis Software version 5.3 (Applied
Biosystems, Foster City, CA). The information obtained from the
sequencing assays was subjected to a BLAST test to determine
identity.
Quantitative real-time PCR. Hypothalamus and pancreatic tissues
were collected in liquid N2 during routine necropsies (colony man-
agement) in three baboons (not those used in the ICV infusion
experiments). Total RNA was extracted from the hypothalamus and
pancreas samples using TRIzol Reagent (Molecular Research Center,
Gaithersburg, MD) and treated with RQ1 DNAse to remove contam-
inating genomic DNA. The quality of the RNA was determined via
ultraviolet light at 230, 260, and 280 nm, and its integrity was
ascertained by staining with ethidium bromide on a 1.2% agarose gel.
Quantitative real-time PCR was carried out in the Applied Biosystems
7000 real-time PCR System. TaqMan Gene Expression Assays (Ap-
plied Biosystems) were specifically designed to amplify GIPR and
glucagon-like peptide-1 receptor (GLP1R) transcripts. GIPR and
GLP1R amplifications were performed using available commercial
primers and a probe (Assay ID Hs006092_m1 and Hs00157705_m1,
Applied Biosystems). 18S rRNA was chosen as the internal control.
Multiplex reactions consisted of 12.5 l of 2	 TaqMan Universal
PCR master mix, 1.25 l of each 20	 assay on demand, 1.5 l of
cDNA, and water to complete 25-l final volume. PCR parameters
were 50°C for 2 min and 95°C for 10 min followed by 50 cycles at
95°C for 15 s and 60°C for 1 min. Validation experiments were
performed to verify that the amplification efficiency of the control was
similar to that of the target genes. A cycle threshold (CT) value in the
linear range of amplification was selected for each sample in triplicate
and normalized to 18S expression levels (
CT).
Phylogenetic analysis. Sequences obtained from clones were
aligned with the orthologous reported genes in GenBank: GIP
(Rattus norvegicus: XM_008767947, Canis lupus familiaris:
XM_003639272, and Homo sapiens: NM_004123) and GIPR (Rattus
norvegicus: NM_012714, Canis lupus familiaris: XM_014119625,
and Homo sapiens: NM_000164) using the CLUSTAL W program.
Peptide and protein sequences were derived by conceptual translation
of the coding sequences.
Statistical analysis. The area under the curve (AUC) was calculated
using the trapezoidal method with linear interpolation between points.
The following AUC variables were analyzed: 1) total AUC (total area
under the curve representing the complete integral of GIP concentra-
tions measured over the entire experimental period of 435 mins), 2)
postprandial AUC (the area under the curve of the postprandial period
from before meal administration to 300min), and 3) postprandial
iAUC(the incremental area under the curve above fasted, baseline
values). All variables were transformed using Box-Cox transforma-
tions to meet assumptions of Gaussian normality before statistical
analysis. Control condition and test condition means were compared
Table 1. GIP and GIPR phylogenetic analysis summary
GIP (1–42) Amino Acid Sequences
GIP-Hs YAEGTFISDYSIAMDKIHQQDFVNWLLAQKGKKNDWKHNITQ
GIP-Ph YAEGTFISDYSIAMDKIHQQDFVNWLLAQKGKKNDWKHNITQ
GIP-cf. YAEGTFISDYSIAMDKIRQQDFVNWLLAQKGKKNDWKHNITQ
GIP-Rn YAEGTFISDYSIAMDKIRQQDFVNWLLAQKGKKNDWKHNLTQ
Predicted GIP (1–42) Amino Acid Sequence Identity Among
Species, %
GIP-Rn GIP-cf. GIP-Hs GIP-Ph
GIP-Rn 100.0
GIP-cf. 97.6 100.0
GIP-Hs 95.2 97.6 100.0
GIP-Ph 95.2 97.6 100.0 100.0
Predicted GIPR (1–466) Amino Scid Sequence Identity Among
Species, %
GIPR-Rn GIPR-cf. GIPR-Hs GIPR-Ph
GIPR-Rn 100.0
GIPR-cf. 80.8 100.0
GIPR-Hs 81.3 86.6 100.0
GIPR-Ph 81.1 86.1 96.8 100.0
GIP, glucose-dependent insulinotropic polypeptide; GIPR, GIP receptor;
Rn, Rattus norvegicus (rat); cf., Canis lupus familiaris (dog); Hs, Homo
sapiens (human); Ph, Papio hamadryas (baboon). The underlined amino acids
denote differences from the human sequence.
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using paired t-tests. Analyses were undertaken using XLSTAT ver-
sion 2015.5.01.23261 (Addinsoft). A two-tailed  level of 0.05 was
used to determine the statistical significance in all tests.
RESULTS
Basic descriptive data are shown in Table 2. The baboons
were young adult male baboons (7–11 yr old) with normal
body weight and normal metabolic status. Body weight was
stable during the testing period (Fig. 1, bottom). No behavioral
abnormalities were noted during any of the experiments; al-
though normal food was withheld during the experimental
periods, food intake after all of the experimental periods was
normal. Normal hematology and biochemistry values were
present throughout the study period. One animal did not go
forward into the experimental phase of the study because of
system compatibility issues and was released from study. Data
on this animal are not included, and data from the remaining
n  3 animals were analyzed.
Fasted GIP concentrations and GIP AUC values are shown
in Table 3. ICV GIP infusion resulted in significantly higher
mean fasted GIP concentrations (P  0.04). Mean  SE GIP
concentrations under control and ICV GIP conditions are
shown in Fig. 2. The significantly higher total AUC GIP
indicated that GIP remained elevated for the duration of the
experimental period (P  0.05). The GIP AUC for the post-
prandial period was also higher under ICV GIP and but did not
reach statistical significance (P  0.057). The GIP iAUC for
the postprandial period was not different under ICV GIP (P 
0.45; Table 3), indicating that the effect on fasted GIP ac-
counted for the entire increased GIP response over the duration
of the experimental period.
Fasted insulin and insulin AUCs are shown in Table 4.
Fasted insulin did not differ between control and ICV GIP
conditions. Total insulin AUC and postprandial insulin AUC
were not significantly different between control and stimu-
lated conditions. However, the postprandial insulin iAUC
was significantly higher (48%) under the ICV GIP infusion
(P  0.01; Table 4). Mean  SE INS concentrations over
the experimental period in control and ICV GIP condition
are shown in Fig. 3A.
Fasted glucagon and glucagon AUCs are shown in Table 4.
Fasted glucagon concentrations were unaffected by ICV GIP
administration. Postprandial glucagon concentrations did not
differ between control and ICV GIP conditions. Glucagon total
AUC was also unaffected by the ICV GIP infusion. Mean 
SE glucagon concentrations over the experimental period are
shown in Fig. 3B.
Fasted PP and PP AUCs are shown in Table 4. Fasted PP
was higher under ICV GIP, but the difference did not reach
statistical significance (P  0.23). With ICV GIP infusion, PP
concentrations were significantly higher (30.1% and 32.7%)
across both the entire experimental period (P  0.003) and
postprandial period (P  0.037), although the incremental
postprandial PP increase did not reach statistical significance
(60.4%, P  0.18). Mean  SE PP concentrations over the
experimental period are shown in Fig. 3C.
Glucose, triglyceride, and free fatty acid concentrations in
the fasted AUCs are shown in Table 5. Neither fasted glucose,
triglyceride, nor free fatty acid concentrations differed under
conditions of ICV GIP and ICV aCSF. Similarly, there were no
significant differences in the three variables across the exper-
imental period or in the postprandial period.
Table 2. Baseline characteristics and fasted metabolic
profiles
Means  SD Minimum-Maximum
Body weight, kg 28.9  2.1 26.5–30.6
Glucose, mg/dl 92.3  1.3 91.0–94.0
GIP, pg/ml 64.4  6.4 55.7–70.9
Insulin, U/ml 20.2  2.2 17.1–22.3
C-peptide, ng/ml 0.490 0.266 0.250–0.667
GLN, pg/ml 120.3  14.1 100.4–130.7
PP, pg/ml 51.9  25.7 15.8–73.4
TG, mg/dl 34.4  3.6 29.3–37.3
NEFA, meq/l 0.260  0.085 0.168–0.372
n 3. GLN, glucagon; PP, pancreatic polypeptide; TG, triglyceride; NEFA,
nonesterified free fatty acids.
Table 3. Effects of intracerebroventricular GIP administration on fasted GIP, total GIP, and postprandial GIP
concentrations
Control (aCSF) GIP (20 pmol·kg1·h1) P Value
Fasted GIP, pg/ml 66.5 8.0 680.6  412.8 0.047*
Total GIP AUC, pg·ml1·min 724  136 3,437  2514 0.041*
Postprandial GIP AUC, pg·ml1·min 417.6  133.7 728.5 261.5 0.057
Postprandial GIP iAUC, pg·ml1·min 351.2  139.2 255.2 224.5 0.448
Data are means SD. Fasted values were calculated as the average peptide concentration at the 30- and 15-min time points. Total area under the curve
(AUC) was calculated as the total AUC from 135 to 300 min. aCSF, artificial cerebrospinal fluid; iAUC, incremental area under the curve. P values are for
means comparisons using paired t-tests. *Statistically significant.
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Fig. 2. Effect of intracerebroventricular (ICV) glucose-dependent insulino-
tropic polypeptide (GIP) on plasma GIP. Plasma GIP concentrations under
continuous ICV artificial cerebrospinal fluid (aCSF) infusion and under con-
tinuous ICV GIP infusion over the experimental period are shown. ICV GIP
infusion was initiated at time120 min, and the meal test was administered
at time  0 min. Data are means  SE; n  3.
E665PERIPHERAL EFFECTS OF BRAIN GIP SIGNALING
AJP-Endocrinol Metab • doi:10.1152/ajpendo.00166.2016 • www.ajpendo.org
Downloaded from www.physiology.org/journal/ajpendo at Univ of North Carolina Chapel Hill (152.002.071.053) on August 12, 2019.
In a separate experiment, GIPR and GLP1R gene expression
were quantified in hypothalamus tissues and compared with
pancreas tissues collected from three baboons (2 female ba-
boons and 1 male baboon). Transcript expression quantifica-
tions are shown in Fig. 4. The GIPR transcript was expressed
in the baboon hypothalamus and was present in quantities
similar to that of GLP1R.
DISCUSSION
GIP exerts complex pleiotropic actions on whole body
metabolism. The abundant and extensive distribution of GIP
and its receptor in the brain suggests important functions of
central nervous system GIP signaling. Our data demonstrate
that central GIP signaling can promote increased plasma
GIP concentrations independent of nutrient stimulation and
increase insulin and PP responses to a meal challenge. These
data provide the first evidence for peripheral metabolic
actions generated by GIP signaling in the central nervous
system.
Multiple studies have provided evidence that GIP func-
tions as a signaling molecule in the central nervous system.
The GIPR transcript and protein are found in multiple
regions of the rat central nervous system and have also been
identified in the hippocampus and temporal lobe of humans
(23). Importantly, neural cells expressing GIP have also
been identified in the rat brain, particularly in the olfactory
bulb, hippocampus, hypothalamus, thalamus, and cerebel-
lum (36). The available data are consistent with central GIP
having neurotrophic effects together with effects on synap-
tic plasticity and central nervous system inflammation. ICV
administration of GIP (1.92 nmol/day) for 5 days increased
the proliferation of hippocampal progenitor cells (37),
whereas acute ICV GIP administration (15 nmol) preserved
long-term potentiation, suggesting an improvement in syn-
aptic plasticity in response to GIP in rats (24). Chronic
peripheral administration of a long-lasting GIP analog pre-
vented the decrease in long-term potentiation induced by
high-fat feeding in rats and improved object recognition
memory and reduced oxidative stress and inflammation in
both the cortex and hippocampus of mice (18, 34). Consis-
tent with the aforementioned findings, GIPR knockout mice
show a reduction in recognition and spatial learning and
exhibit a reduced long-term potentiation in the hippocampus
(20). Therefore, effects of GIP on central nervous system
function have been well described.
Here, we provide evidence for a brain-gut axis signal
generated by central GIP signaling that promotes an in-
crease in peripheral GIP concentrations in the absence of
nutrient stimulation. Presumably, the signal is transmitted
through an efferent neural pathway capable of interacting
with intestinal K cells. Consistent with our findings, brain
insulin signaling has been shown to generate a signal that
promotes its own secretion from the -cell (10, 47, 49). As
with insulin action in the brain, the physiological signifi-
cance of central GIP action is also unclear, and it is not
known whether circulating GIP can cross the blood-brain
barrier. Nevertheless, GIP analogs exerted central nervous
system effects when administered peripherally to rodents,
suggesting that GIP can cross the blood-brain barrier (39).
Studies undertaken in dogs have provided strong evidence
for a brain-gut signaling pathway capable of modulating
GIP concentrations in the peripheral circulation. Plasma GIP
concentrations were increased by ICV administration of
neuropeptide Y (25-g bolus) independent of any nutrient
stimulation (48). Furthermore, ICV neurotensin (1,000
ng·kg1·h1) and bombesin (5.4 ng·kg1·h1) also in-
creased plasma GIP concentrations in both the fasted con-
dition and under duodenal glucose stimulation (50, 51): the
GIP increase in these studies was less than that observed
under ICV neuropeptide Y. Overall, the ICV effects of these
peptides on fasted GIP were 50 –70% less than those seen in
our study. Interestingly, ICV insulin reduced GIP concen-
trations but only during nutrient stimulation (49). The nature
of the putative efferent pathway that mediates this effect
remains unknown.
Our data add to the current literature on the metabolic
effects of central GIP signaling. One prior study has de-
scribed an effect of ICV GIP on energy balance (2). Four
days of ICV GIP infusion (2 nmol/day) in rats resulted in
changes in the expression of genes associated with meta-
bolic regulation in the hypothalamus, including neuropep-
tide Y, and led to weight loss without changes in food
intake, but circulating metabolic peptides were not mea-
sured (2). Our acute infusion experiments were not designed
to address effects of ICV GIP on body weight regulation,
but such studies are warranted in higher species. In support,
Table 4. Effects of intracerebroventricular GIP administration on pancreatic islet peptide secretion
Control (aCSF) GIP (20 pmol·kg1·h1) P Value
Fasted insulin, U/ml 12.8 5.5 15.9 7.3 0.330
Total insulin AUC, U·ml1·min 19,880  4,524 26,361 9,440 0.123
Postprandial insulin AUC, U·ml1·min 11,910  3,210 16,140 5,510 0.152
Postprandial insulin iAUC, U·ml1·min 8,130  3,690 12,030 3,708 0.010*
Fasted GLN, pg/ml 109.9 10.3 99.1 13.0 0.450
Total GLN AUC, pg·ml1·min 38,889  6,917 46,719 10,875 0.599
Postprandial GLN AUC, pg·ml1·min 25,920  4,200 33,420 9,150 0.741
Fasted PP, pg/ml 35.7  28.2 59.6 11.7 0.229
Total PP AUC, pg·ml1·min 42,369  16,965 55,115 20,184 0.003*
Postprandial PP AUC, pg·ml1·min 37,560  15,480 49,830 19,530 0.037*
Postprandial PP iAUC, pg·ml1·min 23,790  14,160 38,160 20,550 0.181
Data are means  SD. Fasted values were calculated as the average peptide concentration at the 30- and 15-min time points. Total AUC was calculated
as the total AUC from 135 to 300 min. iAUC was not reported for GLN as values were below baseline during the postprandial period. P values are for means
comparisons using paired t-tests. *Statistically significant.
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our quantitative real-time PCR assays were positive for
GIPR gene expression in baboon hypothalamic tissue (Fig.
4). We found that hypothalamic expression of GIPR in the
baboon was comparable with that of GLP1R, which is
known to have hypothalamic expression and function.
Our data are consistent with the presence of an efferent
neural signaling system directly regulating GIP release from
intestinal enteroendocrine cells. Consistent with the increase
in plasma GIP, the principal finding of the study, we also
found evidence for increased postprandial plasma insulin
and PP concentrations with ICV GIP infusion. An increase
in PP is typically taken to reflect an increase in cholinergic
input to the pancreatic islets (42). Conflicting data have
been published regarding the influence of the parasympa-
thetic nervous system on GIP release (52), but the weight of
evidence favors noncholinergic involvement in GIP secre-
tion. Moreover, evidence from human studies indicates that
peripheral GIP administration increases PP concentrations
(1, 11, 13). Therefore, the most parsimonious explanation is
that the increase in PP was attributable to the increased
peripheral GIP concentrations and not directly by central
GIP action. Furthermore, the increase in plasma GIP was
also likely to be the direct cause of the higher postprandial
insulin concentrations that occurred under ICV GIP. We did
not find differences in fasted or postprandial glucose con-
centrations in response to ICV GIP administration, but, as
has been previously shown (19), only small increments in
plasma glucose occur in response to oral meal challenges in
healthy glucose-tolerant baboons and leave a very small
window for detecting glucose-lowering effects. The evi-
dence we show for elevations of both PP and insulin with
ICV GIP suggests that central GIP signaling was able to
influence both peptides indirectly by promoting peripheral
GIP release.
A weakness of our study is that we were unable to
quantify whether there was any GIP spillover from the CSF
during our ICV infusion. Our ICV dose of GIP (100
ng·kg1·h1 or 20 pmol·kg1·h1) was chosen based on
assessments of ICV peptide administration to nonhuman
primates, dogs, and rodents. The chosen dose was approx-
imately one order of magnitude less than the typical ICV
dose administered in the aforementioned rodent studies (2,
37). For example, the dose of ICV GIP administered to rats
by Nyberg et al. was 14 times greater than the dose we used
in baboons after accounting for body weight and, hence,
ventricular and CSF volume differences (37). In humans, a
direct intravenous infusion of GIP at a dose three times that
chosen in our study was required to raise plasma total GIP
concentrations up to a maximum of 50% of those seen in
our study (30). Furthermore, in a study by Chia et al. (12) in
humans, a 12-fold higher intravenous GIP infusion rate than
the ICV infusion rate we used in baboons resulted in a
10-fold increase in plasma total GIP from baseline, which is
comparable to the plasma GIP increase that we observed in
baboons. Therefore, it is unlikely that our dose of GIP was
large enough and unlikely that it would have entered the
vasculature fast enough to explain the rate and extent of the
plasma GIP increase observed. Furthermore, a 2.0
pmol·kg1·h1 ICV dose of GIP, used during preliminary
experiments, resulted in a GIP increase of30% of that caused
by the 20 pmol·kg1·h1 dose and is consistent with a dose
response to ICV GIP (data not shown).
Nonhuman primates are important intermediary models
for the translation of rodent findings to humans. Given the
particular importance of nonhuman primates as translational
models for metabolic diseases (7, 40), investigations to
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Fig. 3. Effect of ICV GIP on plasma insulin, glucagon, and pancreatic
polypeptide. A: plasma insulin concentrations under continuous ICV aCSF
infusion and under continuous ICV GIP infusion over the experimental period.
ICV GIP infusion was initiated at time  120 min, and the meal test was
administered at time  0 min. Data are means  SE; n  3. B: plasma
glucagon concentrations under continuous ICV aCSF infusion and under
continuous ICV GIP infusion over the experimental period. ICV GIP infusion
was initiated at time  120 min, and the meal test was administered at
time  0 min. Data are means  SE; n  3. C: plasma pancreatic polypeptide
concentrations under continuous ICV aCSF infusion and under continuous
ICV GIP infusion over the experimental period. ICV GIP infusion was initiated
at time120 min, and the meal test was administered at time 0 min. Data
are means  SE; n  3.
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confirm that gut-brain and brain-gut signaling pathways
found in rodents are operative in nonhuman primates is of
considerable importance. The baboon model is well estab-
lished in the study of all stages of metabolic disease (9, 19,
25, 26, 28, 46). Our ICV infusion methodology advances
previously described ICV infusion techniques applied in
conscious nonhuman primates (3, 4, 43). The externalization
of the ICV cannula line to a remotely controlled pump
enables more control over the ICV infusion and readily
permits acute or continuous chronic studies with minimal
disturbance to the animal. Prior studies of this nature typi-
cally enabled only bolus ICV administrations (33) or
chronic infusions to be undertaken using implantable os-
motic pumps (3, 4, 43). The ICV infusion system described
here enables greater control over the dose quantity, timing,
and duration.
In summary, we found that ICV administered GIP in-
creased peripheral GIP concentrations and influenced post-
prandial islet peptide secretion in nonhuman primates. Our
data are the first to demonstrate a role for central GIP action
in the regulation of peripheral GIP release and the first to
show that central GIP action can influence islet peptide
secretion.
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Table 5. Effects of intracerebroventricular GIP administration on plasma glucose, triglyceride, and free fatty acid
concentrations
Control (aCSF) GIP (20 pmol·kg1·h1) P Value
Fasted glucose, mg/dl 91.7 3.3 93.0  2.9 0.643
Total glucose AUC, mg·dl1·min 307,452  8,557 300,597  2,711 0.403
Postprandial glucose AUC, mg·dl1·min 29,164  2,241 30,049  540 0.503
Postprandial glucose iAUC, mg·dl1·min 1,664  1,483 2,149  798 0.370
Fasted TG, mg/ml 33.7  7.2 32.5  3.5 0.743
Total TG AUC, mg·dl1·min 116,627  19,047 109,836  9,177 0.614
Postprandial TG AUC, mg·dl1·min 11,610  2,834 10,981  1,342 0.769
Postprandial TG iAUC, mg·dl1·min 1,819  1,652 1,552  1,414 0.752
Fasted NEFA, meq/l 0.244 0.061 0.284  0.061 0.517
Total NEFA AUC, meq·l1·min 827.0  248.2 885.3  181.4 0.751
Postprandial NEFA AUC, meq·l1·min 58.8  3.6 62.6  15.5 0.738
Data are means  SD. Fasted values were calculated as the average concentration at the 30- and 15-min time points. Total AUC was calculated as the
total AUC from 135 to 300 min. iAUC was not reported for NEFA as values were below baseline during the postprandial period. P values are for means
comparisons using paired t-tests.
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Fig. 4. Glucose-dependent insulinotropic polypeptide receptor (GIPR) gene
expression relative to glucagon-like peptide 1 receptor (GLP-1R) expression in
the hypothalamus and pancreas of baboons (n  3) by quantitative real-time
PCR. A: mean  SE cycle threshold (CT) values. B: mean  SE 
CT values
(normalized to 18S expression).
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